幽门螺杆菌感染、治疗与结直肠癌风险:遗传易感性的影响
SIT中治疗与29.4年随访结直肠癌风险降低相关(HR=0.47),MITS中总体无获益,但高遗传风险或特定抗原阳性者可能获益。
要点
- 幽门螺杆菌阳性未治疗者结直肠癌风险升高,高遗传风险者更显著。
- SIT中幽门螺杆菌治疗与长期结直肠癌风险降低相关,成功根除者更明显。
- MITS中治疗总体无获益,但高遗传风险或特定抗原阳性者可能获益。
核心结论
- 在两项试验队列的事后观察分析中,幽门螺杆菌感染与结直肠癌风险升高相关。
- SIT中幽门螺杆菌治疗降低结直肠癌风险,MITS中获益仅限于高遗传风险或特定毒力因子亚型感染者。
研究设计与样本
- 在MITS中进一步开展病例队列研究,评估幽门螺杆菌毒力因子血清阳性及宿主遗传易感性与结直肠癌风险的关系。
主要发现
- 与幽门螺杆菌阴性者相比,阳性未接受抗生素治疗者结直肠癌风险显著升高(SIT:HR=2.96,95%CI 1.30-6.71;MITS:HR=1.27,95%CI 1.04-1.55)。
- 对四种幽门螺杆菌特异性抗原(CagA、HpaA、Omp和HP0305)血清阳性者及高遗传风险者(多基因风险评分最高十分位),风险升高尤为明显。
- SIT中幽门螺杆菌治疗与29.4年随访期间结直肠癌风险显著降低相关(HR=0.47,95%CI 0.22-0.99),成功根除者降低更明显(HR=0.38,95%CI 0.15-0.94)。
- MITS中治疗13.8年后总体无获益(HR=1.17,95%CI 0.95-1.43),但高遗传风险者和关键幽门螺杆菌特异性抗原血清阳性者中可见保护效应。
临床怎么用
- 对幽门螺杆菌阳性者,尤其高遗传风险或特定毒力因子亚型感染者,可考虑根除治疗以潜在降低结直肠癌风险。
- 结直肠癌风险评估中可结合幽门螺杆菌感染状态及遗传易感性进行分层。
局限性
- 本研究为对两项已建立试验队列的事后观察分析。
- MITS中治疗对结直肠癌风险的总体获益未观察到,保护效应仅限于特定亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies have suggested a possible association between Helicobacter pylori (H. pylori) infection and an increased risk of colorectal cancer (CRC). OBJECTIVE: We examined the associations of H. pylori infection and H. pylori treatment with incident CRC risk and evaluated whether these associations were modified by genetic susceptibility. DESIGN: This study was based on two randomised trial cohorts: the Shandong Intervention Trial (SIT; n=3365; 1995-2024) and the Mass Intervention Trial in Linqu, Shandong Province (MITS; n=180 284; 2011-2024). Within MITS, we further conducted a case-cohort study to assess CRC risk according to seropositivity for H. pylori virulence factors and host genetic predisposition. RESULTS: Compared with H. pylori-negative individuals, H. pylori-positive individuals who did not receive antibiotic treatment had a significantly higher risk of CRC (SIT: HR=2.96, 95% CI 1.30 to 6.71; MITS: HR=1.27, 95% CI 1.04 to 1.55). The increased risk was particularly evident among individuals seropositive for four H. pylori-specific antigens (CagA, HpaA, Omp and HP0305) and those at high genetic risk (top decile of the Polygenic Risk Score). In SIT, H. pylori treatment was associated with a significantly reduced CRC risk over 29.4 years of follow-up (HR=0.47, 95% CI 0.22 to 0.99), with a greater reduction observed among participants with successful eradication (HR=0.38, 95% CI 0.15 to 0.94). In MITS, no overall benefit was observed 13.8 years after treatment (HR=1.17, 95% CI 0.95 to 1.43). However, a protective effect was apparent among individuals at high genetic risk and among those seropositive for key H. pylori-specific antigens. CONCLUSION: In post hoc observational analyses of two established trial cohorts, H. pylori infection was associated with an increased risk of CRC. H. pylori treatment reduced CRC risk in SIT, whereas in MITS, the benefit appeared to be limited to individuals at high genetic risk or those infected with specific virulence factor subtypes.
引用
- Han X, Xu HM, Liu ZC, et al. Helicobacter pylori infection, treatment and colorectal cancer risk by genetic predisposition: evidence from two randomised trials. Gut. 2026. PMID: 42379837. doi:10.1136/gutjnl-2026-338156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。